特定于imatinib诱导的BCR-ABL突变的T细胞受体,用于采用T细胞治疗
Meng-Tung Hsu1, Gerald Willimsky2,3,4, Leo Hansmann2,3,4,5
1Molecular Immunology and Gene Therapy, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Frontiers in immunology
|February 11, 2025
概括
研究人员在慢性髓性白血病 (CML) 中鉴定了一种来自突变的BCR-ABL (ABL-E255V) 的新表位. 他们开发了针对这种突变的CML细胞的T细胞受体 (TCR),为TKI抗性CML提供了一种新疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 是由BCR-ABL激酶驱动的.
- 氨酸激酶抑制剂 (TKI) 是第一线CML治疗,但面临来自BCR-ABL突变的耐药性.
- 耐药性,特别是来自化合物突变的耐药性,导致复发.
研究的目的:
- 为了研究从突变的BCR-ABL中产生的新表位细胞.
- 为采用T细胞疗法产生新表位特异性T细胞受体 (TCR).
- 针对具有耐药突变的CML.
主要方法:
- 根据HLA-A2结合亲缘关系选择ABL-E255V和ABL-T315I.
- 免疫转基因小鼠与人类的TCR谱限于HLA-A2.2.
- 从响应小鼠中分离和特征E255V特定的TCR.
- 改造人类CD8+ T细胞以表达已识别的TCRs.
主要成果:
- 检测到对ABL-E255V的CD8+T细胞反应,但不是ABL-T315I.
- 隔离了两个特定于E255V的TCR.
- 鉴定了一种具有优越狂热度和没有目标外反应性的TCR候选物.
- 证明了ABL-E255V新表位的自然处理和呈现.
结论:
- 具有E255V突变的HLA-A2+CML细胞可以被特定的TCRs准.
- 这种方法可能有利于TCI耐药CML患者,特别是那些具有复合突变的患者.
- 开发了一种潜在的采用性T细胞疗法,用于抗性CML.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cytotoxic T Cells-mediated Immune Response
832
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
832
T Cell Activation and Clonal Selection
633
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
633
Diversity of Antigen Receptors
492
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
492


